Our monoclonal antibodies are designed to target the tumor without harming healthy cells. These unique and highly specific mAbs are derived from a library of cancer vaccines that is wholly owned by Precision Biologics and have already proved effective against tumors in human trials.

Unlike most cancer drugs on the market today, our therapeutics specifically attack cancer cells—a significant advantage over the “traditional” treatments (mainly chemotherapy and radiation), which obliterate cells indiscriminately and cause multiple side effects. Our diagnostics, meanwhile, could lead to substantially better clinical outcomes by detecting cancers at a much earlier stage. Through these combined efforts, Precision Biologics offers real hope for cancer patients.